Search Within

Connie Wing-Ching Lee Batlevi

  1. "Heiko Schoder"
Formats
  1. Meeting Abstract (20)
  2. Journal Article (9)
Groups
  1. Center for Hematologic Malignancies (29)
  2. Department of Medicine (29)
  3. Hematologic Malignancies, Division of (29)
  4. Lymphoma (29)
  5. Molecular Imaging and Therapy Service (29)
  6. Radiology, Department of (29)

More Groups

People
  1. Heiko Schoder (29)
  2. Alison Moskowitz (24)
  3. Andrew Zelenetz (24)
  4. David Straus (24)
  5. Matthew Matasar (24)
  6. Anita Kumar (22)

More People

Years
  1. 2024 (1)
  2. 2023 (3)
  3. 2022 (6)
  4. 2021 (5)
  5. 2020 (4)
  6. 2019 (3)

More Years

Publications
  1. Blood (13)
  2. Journal of Clinical Oncology (4)
  3. Hematological Oncology (3)
  4. Blood Advances (2)
  5. Blood Cancer Journal (1)
  6. Cancers (1)

More Publications

Publishers
  1. American Society of Hematology (15)
  2. American Society of Clinical Oncology (4)
  3. Wiley Blackwell (3)
  4. Elsevier Inc. (2)
  5. American Association for Cancer Research (1)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (29)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; De Frank, S.; Stewart, C.; Hamlin, P. A.; Matasar, M. J.; Gerecitano, J. F.; Moskowitz, A. J.; Hamilton, A. M.; Zelenetz, A. D.; Drullinsky, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management
    Journal Article

    Sawan, P.; Rebeiz, K.; Schoder, H.; Batlevi, C.; Moskowitz, A.; Ulaner, G. A.; Dunphy, M.; Mannelli, L.
    Medicine (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save